Dr. Glitza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2007 - 2010
Ruprecht Karl University Faculty of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2011 - 2026
OK State Medical License 2020 - 2021
PA State Medical License 2007 - 2012
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease Start of enrollment: 2018 May 02
- Low Dose Ipilimumab with Pembrolizumab in Treating Patients with Melanoma That Has Spread to the Brain Start of enrollment: 2019 Feb 21
Publications & Presentations
PubMed
- 6 citationsRandomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, Jennifer R Wortman, Elizabeth M Burton
Cancer Discovery. 2024-07-01 - 1 citationsAuthor Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross
Nature. 2023-03-01 - 167 citationsNeoadjuvant relatlimab and nivolumab in resectable melanoma.Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross
Nature. 2022-11-01
Journal Articles
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaScott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
- Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaRichard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature
- Join now to see all
Press Mentions
Stage IV Melanoma Survivor: Immunotherapy Clinical Trial Gave Me My Life BackJune 12th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
